About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Oncology mission for Scottish Life Sciences organisations

Ten of Scotlands leading companies and universities specialising in oncology research and development are participating in a trade mission to Massachusetts to develop closer links with global pharmaceutical companies based in the region.

The trip, which has been co-ordinated by Scottish Development Internationals life sciences team, will enable participants to meet with the US-based companies and identify how the work of Scottish based universities and companies could help advance the work of these companies in developing new treatments for cancer related illnesses.

Massachusetts has one of the largest concentrations of life sciences companies in the world with more than 280 companies and 30,000 employees working in the sector and an internationally renowned academic base. The Scottish delegation will be meeting some of the worlds leading pharmaceutical and biotechnology companies including Pfizer, Amgen and Genzyme to help open up new business opportunities.

The US companies will learn about Scotlands leading oncology centres of excellence, including the recently opened Beatson Institute at the University of Glasgows Garscube Estate and the University of Edinburghs Cancer Research Centre, which has been developed in partnership with Cancer Research UK. Leading Scottish companies such as Cyclacel Pharmaceuticals, CXR Biosciences and EiRx Therapeutics will also be attending to identify potential collaborative opportunities with the US-based firms.

Ian Leslie, team leader of the Scottish Development International Life Sciences team says: Boston and the wider Massachusetts state is regarded as one of the worlds leading life sciences locations and home to some of the worlds biggest pharmaceutical and biotech companies. Scotlands world class reputation in the oncology field has helped us get the foot in the door with these global firms and this trip will be hugely important in promoting Scotlands strengths in oncology research and developing new opportunities for collaborative working and new business opportunities for Scottish based organisations.

Scottish Biomedical, a drug discovery services company based in Glasgow, is one of the companies participating and hopes the trip will lead to developing new relationships overseas.

Simon Bury, Business Development Director of Scottish Biomedical, says: The US is obviously a very lucrative market for life sciences and Massachussets is a key market to target. This trip is enabling us to meet with a number of global companies and hopefully develop new relationships to capitalise on our existing contacts overseas.

Oncology is one of Scotlands leading areas of life sciences research and one which has significant commercial potential. There are almost fifty major research groups, centre of excellence and departments within eight Scottish Universities and Research Institutes, working to understand the causes of different cancers and developing new treatments. There is also a growing base of companies actively looking at drug discovery and development to develop new cancer therapeutics.

The full list of organisations participating in the trade mission are: Accuro Biologics Ltd; CXR Biosciences; Cyclacel Pharmaceuticals; EiRx Therapeutics PLC; Nexus Oncology; Scottish Biomedical; University of Aberdeen; University of Dundee; University of Edinburgh and University of Glasgow.

Media Contact

Neil McInnes, Senior Media Relations Executive
Scottish Enterprise
Tel: 0131 313 6196 / 07881 517712
E-mail: neil.mcinnes@scotent.co.uk

Notes to Editors

Scottish Development International works to attract inward investment and knowledge to Scotland in order to help the economy grow. SDI also works to help Scottish companies do more business overseas and to promote Scotland as a good place to live, work and do business. It is jointly operated by the Scottish Executive and Scottish Enterprise. Its work is guided by the global connections theme of the Scottish Executive's Smart Successful Scotland strategy for economic development in Scotland.
Massachusetts (MA) in the US is one of the leading centres for life sciences and has more than 280 pharmaceutical and biotech companies (as well as a world-renowned academic base) together with 30,000 employees. Oncology is a key focus for the state with approximately 50 leading human therapeutics companies located in and around the Boston/Cambridge area. Many large pharmaceutical companies including Pfizer and AstraZeneca have major oncology research facilities in the area, and leading key biotechnology companies including Genzyme and Biogen Idec also have significant capabilities.
Background details of all participating Scottish organisations:
Accuro Biologics Ltd

Accuro Biologics is a research services company providing a new option to those seeking to outsource their needs in antibody and protein engineering, mammalian cell line development and immunogenicity profiling. Created in 2005 and operating from its own fully equipped facilities in the UK, the company services are delivered by a highly experienced laboratory and management team. The company provides a fully flexible approach to its projects and commercial arrangements and seeks to provide access to its advanced capabilities without prohibitive cost and additional royalty burdens to its clients.


EiRx Therapeutics PLC

EiRx Therapeutics (LSE: ERX) is a research-driven healthcare company developing new targeted therapies for the treatment of cancer. The company operates from laboratories in Cork, Ireland, and Aberdeen, Scotland, and has an initial focus on colorectal and breast tumours. EiRx develops novel, small molecule inhibitors of key cellular signalling pathways that have the potential to treat cancer by specific induction of apoptosis in tumour cells. EiRx also undertakes biomarker discovery and validation work using a large biorepository of surgical tumour specimens. EiRx has licensed drug targets to OSI Pharma and MGI Pharma, and has active biomarker collaborations with bioMieux SA and Almac Diagnostics.

http://www.scottish-enterprise.com/sedotcom_home/news-se/news-fullarticle.htm?articleid=192953


hmm very interesting, seems to go with the above article as well


http://www.corkairpark.ie/phase01.htm

EIRX and Pfizer, THEY ARE IN THE SAME BUILDING!!!!, wonder if they are part of the JV

OSI Pharmaceuticals Inc.

OSI Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of oncology products for cancer patients in the United States.

Its flagship product, Tarceva, is an oral, once-a-day, small molecule inhibitor of the epidermal growth factor receptor.

The company also markets Novantrone for the approved oncology indications; and Gelclair for the relief of pain associated with oral mucositis.

Its other drug candidates include OSI-7904L, a liposomal formulation of a potent thymidylate synthase inhibitor, which is in phase II study; OSI-461, an inhibitor of cGMP phosphodiesterases, which is in phase I dose optimization study; and OSI-930, a tyrosine kinase inhibitor, which is in preclinical research stage.

In addition, OSI Pharmaceuticals, through its collaborative drug discovery program, develops CP-547,632, which targets vascular endothelial growth factor receptor and is in Phase II and Phase I trials; CP-868,596 that targets tumor derived angiogenesis and is in Phase I trials; and CP-724,714, which is an oral inhibitor of epidermal growth factor receptor 2 and is in Phase I clinical trial.

Further, its subsidiary, Prosidion Limited, specializes in diabetes and obesity treatment in the United Kingdom.

The company has collaboration agreements with Pfizer, Inc.; Cold Spring Harbor Laboratory; EiRX Therapeutics plc; Genentech, Inc.; and Roche.

OSI Pharmaceuticals is headquartered in Melville, New York.

http://www.lexdon.com/profile/OSI_Pharmaceuticals_Inc./osip.html

so no one left in this then?

katcenka
Yes still accumulating.

im in too
Alex

yawn---zzzzz I'm still here!

are you sure..

yep ! zzz

Still waiting! Not expecting too much at present though, still early days.

we should get a nice update tomorrow.. should start to get exciting late this afternoon

the placing done in January at .0020p was to repay the 245k debt owed to ERX Ltd as this was the agreed price, the debt was not due till end of this month, but this was done early as they are expecting big news to announce and they would not of got the shares at the agreed price.. its all been manipulation of the price by ERX themselves.. the remainder of the placing stayed with the broker for its private clients

Blue having one of his episodes! Please ignore.

You got it Laurie !! :)

INTERIM RESULTS - SIX MONTHS ENDED 31 DECEMBER 2006

Highlights:

cancer collaboration with multinational diagnostics business bioMerieux S.A.
- announced 12 July 2006;
in vivo studies on the company's ERX3722 candidate molecule showed 50%
reduction in breast cancer tumour size without evidence of systemic toxicity
- reported in September 2006;
500,000 in additional funds raised by share placing in September 2006.

Post Balance Sheet Highlight

500,000 in additional funds raised by share placing in January 2007.

http://moneyam.uk-wire.com/cgi-bin/articles/200703300900070451U.html

Prospects

In the current reporting period we have focused on development and exploitation
of our EnPAD(TM) drug discovery technology, which we believe underpins our future
success as a developer of new and better cancer medicines. Inspired by the
success of our work on targeting of the wnt/beta-catenin signalling pathway,
EiRx will continue to invest in EnPAD(TM) and to pursue the development of
promising molecules emerging from these screens, thereby creating value from the
apoptosis research we have undertaken in previous years.

As intimated in our annual report released in December 2006, we believe that we
can best capitalise on the value of our product development efforts by advancing
our candidate therapies at least as far as the late preclinical stage of
development. Reaching this stage will require further investment in the
development of hit compounds from EnPAD(TM) programmes into clinical candidates.
Where appropriate we will seek to develop the necessary skills and competencies
in-house, but academic and commercial partnerships are to be preferred in
instances where they can deliver savings in time or cost. Your board is
considering multiple routes to acquiring the new capabilities we need, including
grant funding, partnering with larger businesses and in-licensing and M&A
options as and when such opportunities arise.

I look forward over the coming months to sharing with you further news of our
progress and our expanding vision for the Company's future. Lastly, I would
like to thank all the management and staff of EiRx for their continued hard work
and commitment and our investors for their continued support.

EiRx Therapeutics PLC - Interim Results for the six months ended 31 December
2006

Your board is
considering multiple routes to acquiring the new capabilities we need, including
grant funding, partnering with larger businesses and in-licensing and M&A
options as and when such opportunities arise.


well that kind of backs up the JV rumour, I understand ERX did not want to deliver results until next week as there is more news they wanted to add, but were forced by there brokers to issue the results.

PH
I agree still happy to hold and accumulate.

Mike111D - 4 Apr'07 - 23:23 - 13198 of 13203


ZYC300 gets a mention as part of the MGI programme for focussed pipeline investments, as per the presentation delivered at the Lehman Brothers 10th annual global healthcare conference on March 20th 2007:

http://library.corporate-ir.net/library/73/738/73842/items/236522/LehmanBrothersPresentation.pdf

Increasing focus being given to the MGI development pipeline, calling out ZYC300:

MGI has decided to consolidate its drug-development operations from its headquarters in Minnesota and a facility in Baltimore to the former Zycos location in Lexington, with plans to nearly triple the number of workers the company now employs in Massachusetts, according to the company's chief scientific officer, Mary Lynne Hedley.

Hedley said that work at the Lexington facility would involve developing MGI's approved cancer drug Dacogen for additional uses as well as bringing the company's other key cancer drug candidates, such as Amolimogene and ZYC300, through clinical trials.

http://masshightech.bizjournals.com/masshightech/stories/2007/01/29/story10.html

As we know trial results for a study of ZYC300 administered with Cyclophosphamide are due this month:

http://clinicaltrials.gov/ct/show/NCT00381173;jsessionid=631F1AF72EC7FC29976FE9B2A6BC793B?order=38

http://utm-ext01a.mdacc.tmc.edu/dept/prot/clinicaltrialswp.nsf/Index/2006-0488

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy

Purpose: The carcinogen activator cytochrome P450 1B1 (CYP1B1) is expressed on almost all human tumors with rare expression on normal tissues. Anti-CYP1B1-specific T cells kill CYP1B1-expressing tumors, providing the rationale to examine CYP1B1 as a target for immunotherapy. Experimental Design: ZYC300, a plasmid DNA of CYP1B1 encapsulated in biodegradable polyDL-lactide-coglycolide microparticles, was used in a phase I clinical trial to treat 17 patients with advanced stage, progressive cancer. ZYC300 was administered i.m. at a fixed dose of 400 μg every other week for up to 12 doses. Results: Thirteen patients received six vaccinations and five received all 12 doses. No significant adverse events were observed. Six patients developed immunity to CYP1B1, three of whom developed disease stabilization. All but 1 of 11 patients who did not develop immunity to CYP1B1 progressed and did not respond to salvage therapy. Five patients who developed immunity to CYP1B1 required salvage therapy for progressive metastatic disease and showed marked response to their next treatment regimen, most of which lasted longer than 1 year. Conclusions: The association between immunity to CYP1B1 and response to next salvage therapy was not expected. Because six of the seven patients who had clinical benefit regardless of the nature of salvage therapy had developed immunity to CYP1B1, it seems highly unlikely that this occurred by chance alone. Regardless of the mechanism(s) that induced tumor regression, these findings force us to rethink how the generation of antitumor immunity might be integrated into the treatment of cancer.

http://cat.inist.fr/?aModele=afficheN&cpsidt=16856410

potatohead is a mad ramper. He calls himself BlueXXXX ( XXX = Kitten, Dolphin, etc) on a d v f n and he tells very big lies, he makes things up about ERX, joint ventures, M&A with Johnson & Johnson/GSK. Claims that other companies drug candidates belong to ERX etc. You would be very wise to ignore absolutely everything he says and do your own research.

gilbertD1
We all know who ph is most of us were already on this share before he arrived cheers for the advice anyway.